pharma · Retinitis Pigmentosa · Dyslipidaemia
HRA Pharma
Laboratoire HRA Pharma
HRA Pharma clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- CHATILLON, USA
- Employees
- 121
- Programs
- 11
- Drugs
- 17
- Patents
- 0
HRA Pharma projects
4 ClinicalTrials.gov programs sponsored by HRA Pharma.
HRA Pharma has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ARG-01-2024
Laboratoire HRA Pharma
rhinosinusitis not requiring antibiotic therapy, rhinopharyngitis not requiring antibiotic therapy, Acute rhinitis not requiring antibiotic therapy
1 trial -
Coagulation Factor VIIa (Recombinant)
Laboratoire HRA Pharma
Hemophilia
1 trial -
Placebo
Laboratoire HRA Pharma
Leber congenital amaurosis (LCA)
1 trial -
Pravafenix 40 mg/160 mg hard capsules
Laboratoire HRA Pharma
Dyslipidaemia
1 trial
Frequently asked questions
How many clinical projects does HRA Pharma have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.